Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Anavex Life Sciences Corp. (AVXL)

11.89   0.53 (4.67%) 11-25 13:00
Open: 11.3 Pre. Close: 11.36
High: 11.95 Low: 11.27
Volume: 778,695 Market Cap: 927(M)

Technical analysis

as of: 2022-11-25 1:55:20 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 15.89     One year: 17.8
Support: Support1: 10.97    Support2: 9.12
Resistance: Resistance1: 13.6    Resistance2: 15.23
Pivot: 12.56
Moving Average: MA(5): 11.75     MA(20): 12.44
MA(100): 11.04     MA(250): 11.54
MACD: MACD(12,26): 0.1     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 13.7     %D(3): 13.7
RSI: RSI(14): 48.1
52-week: High: 20.23  Low: 7.13
Average Vol(K): 3-Month: 892 (K)  10-Days: 1,133 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AVXL ] has closed above bottom band by 34.3%. Bollinger Bands are 57.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.9 - 12.01 12.01 - 12.08
Low: 10.87 - 11.01 11.01 - 11.1
Close: 11.19 - 11.43 11.43 - 11.57

Company Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Headline News

Fri, 25 Nov 2022
Pre-Market Earnings Report for November 28, 2022 : PDD, HTHT, AVXL - Nasdaq

Wed, 23 Nov 2022
Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St

Tue, 22 Nov 2022
Anavex Life Sciences (AVXL) is scheduled to report quarterly earnings on Tuesday. - Best Stocks

Mon, 14 Nov 2022
Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback - Seeking Alpha

Fri, 11 Nov 2022
Anavex Life Sciences Corp (AVXL) Stock: What Does the Chart Say Friday? - InvestorsObserver

Tue, 08 Nov 2022
Anavex Life Sciences Corp (NASDAQ: AVXL) On Watch as Biotech to Present Results for its Phase 2b/3 Trial for blarcamesine for Alzheimer’s Disease - MicroCap Daily

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 78 (M)
Shares Float 76 (M)
% Held by Insiders 3 (%)
% Held by Institutions 32.1 (%)
Shares Short 10,110 (K)
Shares Short P.Month 10,260 (K)

Stock Financials

EPS -0.58
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.92
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -17.1
Return on Equity (ttm) -29.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -28 (M)
Levered Free Cash Flow -10 (M)

Stock Valuations

PE Ratio -20.51
PEG Ratio 0
Price to Book value 6.16
Price to Sales 0
Price to Cash Flow -33.26

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.